Special Issue "Nanotechnology to Counter the Off-Target Toxicity of Therapeutics"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 2305
Nanotechnology has revolutionized treatment regimens by replacing them with ones that are more effective, less toxic, and positively impact survival. Nanotechnology has been used to treat diseases, promote wellness, and reduce health disparities by developing new tools to understand human variability at the molecular and cellular levels.
In efforts to improve the efficacy of diagnostic assays and therapeutic agents, precise molecular recognition of disease-specific markers remains a major hurdle. Achieving only ‘On-Target’ therapeutics will also require technologies beyond this one-size-fits-all approach. Nanotechnology enables innovations in the development of instrumentation, imaging modalities, and spectroscopic techniques to support and empower these approaches, enabling bias-free routes to achieve a holistic understanding and treatment of disease states with spatiotemporal precision. Point-of-use platforms seek to bring bioanalytical assays to the individual, thus, enhancing the speed with which results are available to caregivers, to exert rapid changes in treatment regimens, to benefit their patients’ health and wellness. Seminal advances in the miniaturization of instrumentation have led to a growing range of smart, accurate, and low-powered biomedical devices and portable biomolecular diagnostics, with the ultimate goal of rendering sensors capable of personalized bioassays, supporting therapies targeted to the individual.
This Special Issue aims to highlight nanotechnology-enabled precision therapeutics/therapies or nanotechnology-based analytical platforms to guide therapeutic regimens to benefit all populations
Dr. Prakash D. Nallathamby
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.